Biomarin Pharmaceutical (BMRN) Trading With Heavy Volume Before Market Open
Trade-Ideas LLC identified
(
) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Biomarin Pharmaceutical as such a stock due to the following factors:
- BMRN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $146.7 million.
- BMRN traded 212,579 shares today in the pre-market hours as of 9:10 AM, representing 12.3% of its average daily volume.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in BMRN with the Ticky from Trade-Ideas. See the FREE profile for BMRN NOW at Trade-Ideas
More details on BMRN:
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently there are 14 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 2 rate it a hold.
The average volume for Biomarin Pharmaceutical has been 1.5 million shares per day over the past 30 days. Biomarin has a market cap of $13.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.57 and a short float of 4% with 3.31 days to cover. Shares are down 23.8% year-to-date as of the close of trading on Tuesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Biomarin Pharmaceutical as a
. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.
Highlights from the ratings report include:
- BIOMARIN PHARMACEUTICAL INC's earnings per share declined by 23.3% in the most recent quarter compared to the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, BIOMARIN PHARMACEUTICAL INC reported poor results of -$1.15 versus -$0.92 in the prior year. For the next year, the market is expecting a contraction of 93.5% in earnings (-$2.23 versus -$1.15).
- The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Biotechnology industry average. The net income has significantly decreased by 26.1% when compared to the same quarter one year ago, falling from -$67.50 million to -$85.14 million.
- The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Biotechnology industry and the overall market, BIOMARIN PHARMACEUTICAL INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has decreased to -$171.55 million or 24.48% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
- Looking at the price performance of BMRN's shares over the past 12 months, there is not much good news to report: the stock is down 43.13%, and it has underformed the S&P 500 Index. In addition, the company's earnings per share are lower today than the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- You can view the full Biomarin Pharmaceutical Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.